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Abstract
Background: Our understanding of the etiology, pathophysiology, phenotypic diversity, and progression of
Parkinson’s disease has stagnated. Consequently, patients do not receive the best care, leading to unnecessary
disability, and to mounting costs for society. The Personalized Parkinson Project (PPP) proposes an unbiased approach
to biomarker development with multiple biomarkers measured longitudinally. Our main aims are: (a) to perform a set
of hypothesis-driven analyses on the comprehensive dataset, correlating established and novel biomarkers to the rate
of disease progression and to treatment response; and (b) to create a widely accessible dataset for discovery of novel
biomarkers and new targets for therapeutic interventions in Parkinson’s disease.
Methods/design: This is a prospective, longitudinal, single-center cohort study. The cohort will comprise 650 persons
with Parkinson’s disease. The inclusion criteria are purposely broad: age≥ 18 years; and disease duration ≤5 years.
Participants are followed for 2 years, with three annual assessments at the study center. Outcomes include a clinical
assessment (including motor and neuro-psychological tests), collection of biospecimens (stool, whole blood, and
cerebrospinal fluid), magnetic resonance imaging (both structural and functional), and ECG recordings (both 12-lead
and Holter). Additionally, collection of physiological and environmental data in daily life over 2 years will be enabled
through the Verily Study Watch. All data are stored with polymorphic encryptions and pseudonyms, to guarantee the
participants’ privacy on the one hand, and to enable data sharing on the other. The data and biospecimens will
become available for scientists to address Parkinson’s disease-related research questions.
Discussion: The PPP has several distinguishing elements: all assessments are done in a single center; inclusion of
“real life” subjects; deep and repeated multi-dimensional phenotyping; and continuous monitoring with a wearable
device for 2 years. Also, the PPP is powered by privacy and security by design, allowing for data sharing with scientists
worldwide respecting participants’ privacy. The data are expected to open the way for important new insights,
including identification of biomarkers to predict differences in prognosis and treatment response between patients.
Our long-term aim is to improve existing treatments, develop new therapeutic approaches, and offer Parkinson’s
disease patients a more personalized disease management approach.
Trial registration: Clinical Trials NCT03364894. Registered December 6, 2017 (retrospectively registered).
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Background
Parkinson’s disease (PD) is the second most prevalent
degenerative brain disease [1]. PD will become even more
prevalent in our aging society, with an expected pandemic
rise and doubling of the current patient volume by the
year 2040 [2]. From a systems-biology perspective, PD is
seen increasingly as an umbrella term for a group of
underlying disorders that all exhibit unique genetic, bio-
logical, and molecular abnormalities, and that are likely to
respond differentially to a given therapeutic approach [3].
Although adhering to the concept of PD as a single
disorder has been useful for the development of symptom-
atic treatments, it has hindered progress when applied to
the development of new interventions that can decelerate
or even arrest disease progression [4]. Moreover, our un-
derstanding of the basic etiology, pathophysiology, pheno-
typic diversity, and progression of PD has stagnated, partly
due to the limited patient diversity captured in study
cohorts, and partly because patients were not studied in
sufficient detail (i.e., limited set of outcomes, or brief
follow-up periods). As a result, patients do not receive the
best care they deserve, leading to unnecessary disability
and to mounting costs for society.
To date, there are no reliable biomarkers that can help
to predict the widely varying differences between patients
in prognosis, rate of progression, time to development of
important milestones (e.g., time to first fall, or time to
onset of dementia), or treatment response. Cohort studies
evaluating multiple outcomes simultaneously are needed
to address the multi-dimensional nature of PD. Although
several of such cohorts exist and have already shown their
merits [5–12], they all have their limitations. These limita-
tions relate to, e.g., the inclusion of a highly selective pa-
tient population (rather than a more real-life population),
to the multi-center design (introducing variability in
assessments and procedures across centers), the lack of
detailed clinical and genotyping baseline and follow-up in-
formation, the lack of repeated and advanced neuro-
imaging, and the absence of wearable sensors to support
the follow-up period.
The Personalized Parkinson Project (PPP) intends to
build a cohort that has unique characteristics to overcome
the limitations of previous studies. The project will focus
on the inclusion of “real world” representative patients with
PD, who will undergo extremely detailed phenotyping,
including microbiome & inflammation, high-quality
repeated neuroimaging with repeated MRI scans and fMRI.
All assessments are performed at a single centre and
optimal retention strategies will be applied. In addition,
we seek to perform day-to-day patient monitoring with a
multi-sensor wearable device that allows continuous real-
time data collection in the free-living environment during
a 2-year follow-up period using a state-of-the-art and
convenient wearable device. The PPP aims to identify
biomarkers that can assist in predicting differences in
prognosis and treatment response between patients. The
insights generated by the PPP will pave the way to
improve existing treatments, to create new therapeutic
approaches, and to develop a more precise and personal-
ized disease management approach. Additionally, the PPP
cohort applies unprecedented digital security standards,
supporting data sharing with qualified researchers world-
wide, allowing them to add their research capacity to
further address the main aims of this study.
Methods/design
Study design
This is a prospective, longitudinal cohort study involving
650 persons with PD. During a 2-year follow-up period,
participants will undergo three extensive annual assess-
ments, and continuously wear a multi-sensor investiga-
tional research device (the Verily Study Watch). The 5-
year study is being carried out in one academic hospital
in the Netherlands (the Radboud university medical
center in Nijmegen). Participants will be included be-
tween October 2017 and December 2019, or longer until
the recruitment target of 650 participants is achieved.
Throughout the study period, a panel of 20 Parkinson
patients will advise the research team on aspects of the
study. For example, during the preparation phase, the
panel advised on the design of the study procedures, on
recruitment materials, and on subject retention strategies.
Study population
Participants are eligible for this study if they meet the
following criteria:
 Parkinson’s disease duration ≤5 years, defined as
time since the diagnosis made by a neurologist;
 18 years of age or older;
 Able to read and understand Dutch;
 Willing, competent, and able to comply with
all aspects of the protocol, including follow-up
schedules and biospecimen collections; and
 Providing written informed consent.
Patients with co-morbidity are explicitly NOT excluded
from participation. Candidates will only be excluded in
the case of existing co-morbidities that are sufficiently
severe so as to hamper the interpretation of parkinsonian
disability. Other exclusion criteria include contraindica-
tions to magnetic resonance imaging (MRI), pregnancy or
breastfeeding, and/or nickel allergy (as components of the
Study Watch contain this metal). For the lumbar puncture
additional contraindications are defined, i.e., being treated
with an anticoagulant medication or clinical evidence of
structural cerebral abnormalities.
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To guarantee a balanced study cohort, a stratification
inclusion model will be applied, by gender (men/women),
age (21–45;46–55; 56–65; ≥66 years) and disease duration
(< 2½ years; ≥2½ years). Consequently, half of the cohort
will have a disease duration of maximally 2½ years at the
moment of inclusion, which will also allow us to the impact
of very early signals and markers on disease progression.
Recruitment and enrolment
In the Netherlands, approximately 40,000 people are
diagnosed with PD, with an incidence of 8,000 newly
diagnosed patients annually. Recruitment strategies that
have proven to be successful in past clinical trials will be
adopted [13–16]. First of all, the Dutch national Parkin-
sonNet, an existing nationwide clinical infrastructure in
the Netherlands with 3,200 specialized PD professionals,
will bring the study to the attention of its members [17–19].
Next, healthcare providers working in university medical
centers and community-based hospitals treating PD patients
and the Dutch Parkinson Patient Association, representing
over 8,000 Dutch Parkinson patients, will promote the
study. Finally, various social media announcements and
media appearances will be used to reach the target popula-
tion. All of those interested in the study will be redirected
to the study website (www.parkinsonopmaat.nl), where
detailed information can be found, along with an ap-
plication form.
After application, participants receive at least two
personal sessions with a dedicated trial assessor by
phone to screen eligibility and provide further informa-
tion. During these calls, prior to inclusion, the assessor
verifies that the participant is competent, by discussing
the participant’s decision and reasoning. The assessor
can decide to not include a potential participant because
of limitations in cognitive status that would keep the
person from providing informed consent. If the patient
is willing and able to participate, (s)he is invited to
return a signed informed consent form by mail to the
study center and the date for the baseline visit is booked.
Once informed consent is obtained, access to the medical
records of the treating neurologist and general practi-
tioner is requested to verify the diagnosis of Parkinson’s
disease and check whether or not patients are diagnosed
with clear dementia in the eyes of the patient’s own phys-
ician. Those participants without a confirmed diagnoses
and/or presence of dementia, will not be included, despite
initial consent. During the first study visit, prior to the
assessments, the trial assessor reconfirms that the patient
understands the consequences of participation. During
the follow-up visits the assessor will verify the cognitive
status of the participants in a similar manner. The infor-
mal caregiver can also signal a marked cognitive decline
that would hamper the patient’s inability to understand
the implications of continued participation. Patients who
are no longer able to provide a valid informed consent for
participation will be excluded from further follow-up, but
the data obtained until that moment will be kept in the
central database.
Study procedures and assessments
Participants visit the study site three times for data col-
lection: an initial baseline visit and two annual follow-up
visits. Data collection during each visit takes a full day
and can be spread out over a 1.5-day period if desired by
the patient. Prior to each visit, study participants will be
offered a complimentary hotel stay, thereby reducing the
need for patients living far away from the study center
to travel long distances in the early morning. Patients
arrive at the study site in the morning in a practically
defined OFF state, i.e., at least 12 h after having taken
their last dopaminergic PD medication.
During the three in-clinic visits, detailed clinimetrics
with multiple standardized evaluations for motor,
neuropsychological, and other PD-related assessments
are performed, while wearing the Verily Study Watch
(see Table 1 for an overview). Some of the motor
assessments are performed first in a clinically defined
OFF state and repeated after the participant has taken
the regular first morning dose of medication(s) and has
subjectively reached a typical ON state. The medical
examination and clinical assessments are videotaped
with a static camera and/or recorded for audio signals,
unless the subject declines. The video-recording are
for local use only and will not be shared within the
study. In addition, relevant biospecimens are collected,
i.e., whole blood for plasma/peripheral blood mono-
nuclear cells (PBMC)/serum/DNA/RNA, cerebrospinal
fluid (CSF), and stool for longitudinal genotypic and
phenotypic assays. CSF will be collected only at base-
line and after 2 years and is the single optional element
of the study protocol. Local anaesthesia will be
provided to minimize patient burden and atraumatic
needles will be used. Moreover, using advanced MRI,
at baseline and after two years, indices of in vivo brain
structure and function are obtained, using an exten-
sion of the UK Biobank protocol [20, 21]. The PPP
MRI protocol captures structural MRI (T1 and T2-
weighted imaging, diffusion tensor imaging (DTI) and
quantitative susceptibility mapping (QSM)), resting
functional MRI (fMRI), and two task-related fMRI
studies. The tasks probe both primary brain dysfunc-
tion, i.e. basal ganglia dysfunction, as well as cerebral
compensatory activity. An additional surface electro-
myography is performed during MRI scanning to
monitor tremor, so artifacts can be removed [22].
Finally, to assess autonomic dysfunction, study sub-
jects wear a Holter monitor during each in-clinic visit
(except while being in the MRI scanner), and a 12-lead
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Table 1 Overview of included study measures and scales in the Personalized Parkinson Project
Method Outcome Scales Visit 1
(Baseline)
Visit 2
(1 Year)b
Visit 3
(2 Years)b
After each
visitc
Assessed by trial
assessor
Motor functioning
in OFFa state
- MDS-UPDRS-III (including H&Y stage) X X X
- Timed up-and-go test X X X
- Standing leg test X X X
- Rapid turning test X X X
- Pegboard test X X X
Motor functioning
in ONastate
- MDS-UPDRS-III (including H&Y stage) X X X
- TUG X X X
- MDS-UPDRS-IV X X X
- Standing leg Test X X X
- Rapid Turning Test X X X
- Pegboard Test X X X
- Grip strength X X X
Neuropsychological
symptoms
- MDS-UPDRS-I X X X
- MoCa (with alternative versions during
follow-up)
X X X
- Phonemic and semantic Fluency X X X
- Brixton Spatial Anticipation Test X X X
- 15 Words Test X X X
- Benton Judgment of Line Orientation X X X
- Letter Number Sequencing X X X
- Symbol Digit Modalities Test X X X
Activities of daily living - Modified Schwab and England scale X X X
Demographics and lifestyle - Medical history X – –
- Lifestyle exposure X – –
- Medication (Parkinson and other) X X X
- Non-pharmacologic Treatments X X X
Biospecimens - Stool X X X
- EDTA Plasma (DNA) X – –
- PAX Gene (RNA) X X X
- peripheral blood mononuclear cells (PBMCs) X – –
- Plasma (no PBMC) X X X
- Serum X X X
- CSF X – X
Autonomic function - Holter ECG X X X
- 12-lead ECG X X X
- Blood pressure (standing and supine) X X X
Brain structure and function - Structural MRI (T1, T2, FLAIR, DTI, QSM) X – X
- Functional MRI (resting state,
task-related)
X – X
Verily Study Watch Physiological and
environmental parameters
- PPG Continuous data collection,
up to 23 h a day.
- ECG
- IMU including 3-axis accelerometer
and 3-axis gyroscope
- EDA
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ECG is performed while the subject is supine. Blood pres-
sure is measured in both supine and standing positions,
from which the presence of orthostatic hypotension will be
assessed.
After each visit participants complete a set of validated
questionnaires at home, including questionnaires about
medication use, quality of life, lifestyle, neuropsychological
symptoms, autonomic symptoms, sleep, and vision, among
others [23–33]. These questionnaires are completed within
4 weeks after each visit, via an online survey module.
Finally, a copy of the medical record of the partici-
pant’s primary care physician is requested. This provides
a rich information source of known and unknown
markers of disease progression.
Participants are asked to wear the Verily Study Watch
preferably 24/7, except during charging, for 2 years.
During the baseline visit, the trial assessor discusses the
importance of ambulatory monitoring with the subject
and explains and demonstrates the use of the Study
Watch. Moreover, a paper-based user manual is made
available to each participant. The Verily Study Watch is
an investigational, non-CE marked, multi-sensor wear-
able device designed to extend data collection for clinical
studies beyond trial sites and into the free-living envir-
onment. For its use in the Personalized Parkinson
Project approval is obtained by the Dutch Health and
Youth Care Inspectorate. The device enables the collec-
tion of physiological and environmental data about ac-
celeration/orientation, pulse rate, electrodermal activity
(EDA), electrocardiogram (ECG), barometric pressure,
relative humidity, environmental temperature, and ambi-
ent light level. The Verily Study Watch is intended for
passive data collection only, with minimal information
communicated to the user via the device (Fig. 1). Data
Table 1 Overview of included study measures and scales in the Personalized Parkinson Project (Continued)
Method Outcome Scales Visit 1
(Baseline)
Visit 2
(1 Year)b
Visit 3
(2 Years)b
After each
visitc
- Skin temperature
- Relative humidity
- Barometric pressure
- Ambient light level
Self reported patient
questionnaires
Neuropsychological
symptoms
- BDI-II X
- QUIP-RS X
- Apathy scale X
- STAI X
Sleep disorders - SCOPA- sleep X
- Epworth sleepiness scale X
Quality of life - PDQ-39 X
- SF-12 X
Various - MDS-UPDRS-II X
- SCOPA- aut X
- RBD questionnaire X
- Wearing-off questionnaire X
- New Freezing of Gait Questionnaire X
- Radboud Oral Motor Inventory X
- Screening Questionnaire on
Visual Impairment
X
- PASE X
Self reported caregiver
questionnaires
Burden - CSI X
BDI Beck Depression Inventory, CSF Cerebro-Spinal Fluid, CSI Caregiver Strain Index, DNA Deoxyribonucleic acid, DTI Diffusion Tensor Imaging, ECG
electrocardiogram, EDA electrodermal activity, EDTA Ethylene Diamine Tetra Acid, FLAIR Fluid Attenuation Inversion recovery, H&Y Hoehn & Yahr, IMU Inertial
Measurement Unit, MDS-UPDRS-I/II/III/IV Movement Disorders Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale, non-motor experiences
of daily living section (I), motor experiences of daily living section (II), motor examination section (III), and motor complications section (IV), MMSE Mini Mental
State Examination, MoCa Montreal Cognitive Assessment, MRI Magnetic Resonance Imaging, PASE Physical Activity Scale for the Elderly, PAX genes Paired box
genes, PBMC Peripheral Blood Mononuclear Cell, PDQ-39 39-item Parkinson Disease Questionnaire, PPG photoplethysmograph, QSM Quantitative Susceptibility
Mapping, QUIP-RS Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale, RBD Rapid eye movement sleep Behaviour Disorder,
RNA Ribonucleic Acid, SCOPA-aut SCales for Outcomes in PArkinson’s disease, autonomic function section, SCOPA-sleep SCales for Outcomes in PArkinson’s
disease, sleep section, SF-12 12-item Short Form, STAI State Trait Anxiety Inventory for Adults, TUG Timed Up and Go test
aMedical examinations & clinical assessments will be videotaped unless a subject declines; b ± 60 days; c within 4 weeks after each in-clinic visit
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from the Verily Study Watch are encrypted and sent
securely to the Verily cloud using a USB syncing/char-
ging cradle and wireless connectivity bridge (the Verily
Study Hub). The Study Watch has been deployed in sev-
eral studies, mainly in the United States, including the
Baseline Health Study [34] and the Parkinson Progres-
sion Markers Initiative (PPMI) [5].
Subject retention strategies
Throughout the study, a dedicated helpdesk proactively
assists participants, addresses problems and questions,
and solves/communicates issues related to the execution
of the trial. In addition to the study helpdesk, assigning a
personal trial assessor to each participant during the entire
study period is an important retention strategy. Partici-
pants are kept informed about the study with newsletters
and participant events. In addition, the study website will
be used for regular recruitment updates, combined with
an extensive information package on topics that are found
to be relevant for people with PD. The topics will be
selected by the participants themselves.
Quality management
All study procedures are being performed at a single
centre, the Radboud university medical center. The
study assessors were extensively trained and certified for
the various elements of the protocol, before enrollment
of the first study subject. Written standardized operating
procedures (SOPs) were developed, detailing all data col-
lection and study procedures. At least once a month, the
study team discusses unexpected situations and prob-
lems encountered with execution of the study protocol.
Frequent monitoring of the data quality ensures a timely
identification of both systematic and incidental devia-
tions. On a monthly basis an independent study monitor
checks key elements of the study, e.g., inclusion rates,
informed consents, data entry, protocol deviations, and
(serious) adverse event reporting. If quality control
issues emerge, the study protocol and SOPs will be
amended and trial assessors will be retrained.
Data management and protection to subject privacy
Data protection
For the PPP study, a Polymorphic Encryption and Pseudo-
nymization (PEP) infrastructure was developed and is used
to protect the data and the privacy of the participants [35].
For each participant, this method generates unique pseu-
donyms for the different participating research groups. The
PEP was created to deal with the rigidity of the traditional
encryption/decryption process by using polymorphic
encryption right after collection and before storage. In that
manner, there is no need to a priori fix in the encryption
key for the data. The PEP system allows different
researchers to have access to the entire dataset or only a
subset of the dataset with a specific decryption key. In
addition, the polymorphic encryption method avoids the
combination of different datasets by different decryption
key-holders, since each key only decrypts that subset of the
data. Due to its additional security, the PEP is an ideal
approach to manage sensitive personal data with reduced
risk of a participant’s privacy being violated.
Data handling and storage
An electronic data capture and management system,
Castor (https://data.castoredc.com), is used for the collec-
tion of most study data. This is a GCP-certified data man-
agement system with servers in accordance with the
NEN7510 norm for information security in healthcare. All
medical examinations and clinical assessment data are en-
tered directly into Castor and stored in a pseudonymized
manner. Similarly, Castor is used by subjects to complete
the online questionnaires as part of the annual assessment.
Holter ECG and 12-lead ECG data are also stored directly
into Castor. MRI data is collected and stored at the Don-
ders Center for Cognitive Neuroscience (DCCN), follow-
ing their data management procedures: after data
collection a backup is stored locally on the DCCN data
Fig. 1 The Verily Study Watch (an Investigational Device), along with syncing/charging cradle and Study Hub. The photographs are owned by
Verily and have a copyright. Verily kindly granted written permission to use and adopt if for this publication
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servers; a copy is transferred to PEP, based on a PEP-
generated pseudonym. Participating researchers can ac-
cess data only via PEP. For the Verily Study Watch data,
Verily will first preprocess the data and subsequently up-
load it to PEP. Verily only knows the device identifiers,
but does not know the study participants.
All biospecimens are biobanked at the Radboud
Biobank (Nijmegen, the Netherlands) [36], with their
sample tracking system, sample processing system op-
eration procedures, and standardized sample storage
conditions being employed. In addition to Radboud’s
laboratory capabilities, some sample processing will be
performed by Verily Life Sciences. Verily has an on-
site biobank as well as laboratories for molecular
biology, chemistry, immunology, and systems biology
including a population scale genomics facility. Verily’s
laboratories use a laboratory information system for
sample tracking, and all staff are trained on standard
operation procedures for sample biobanking and
processing. PEP pseudonyms for all samples have been
added to both biobanks’ sample tracking systems.
Statistical analyses
The primary objective of this study is to evaluate the
rate of disease progression and, ultimately, to evaluate
treatment response with respect to the presence of both
established and potential biomarkers. More specifically,
we will address two objectives in the short term:
1. The individual associations between potential
biomarkers and disease progression in Parkinson’s
disease, with progression being expressed in terms
of rate of decline in two key outcome domains of
the disease, i.e., motor functioning and cognitive
functioning.
2. The prediction of disease progression after 1 year
and 2 years on each of the two outcome domains.
Motor functioning will be determined using the score
from the motor section (part III) of the Movement Disor-
ders Society-sponsored revision of the Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) [37], measured in the
OFF state. Cognitive functioning will be determined using
the score from the Montreal Cognitive Assessment scale
(MoCA), a scale for global cognitive abilities that is vali-
dated for use in Parkinson’s disease [38].
For each of the two outcomes, the prediction will be
made for absolute change scores (as a continuous meas-
ure) and clinically important change scores or clinically
important threshold (as a dichotomous measure). For
motor functioning, the dichotomous measure is a change
of at least 5.5 [39, 40]. For cognitive functioning, the
dichotomous measure is a follow-up score below 23.5
[41]. Both will be calculated over the first year of follow-
up, as a measure for short-term disease progression
(hence with direct clinical relevance for near-term treat-
ment decisions), and over 2 years of follow-up, as a meas-
ure for mid-term prognosis.
The association between a potential biomarker and the
change in the PD outcome (objective 1) will be evaluated
with a multivariable linear model, adjusted for age and
disease duration. For objective 2, a variety of different
model building methods (e.g., forward stepwise logistic
regression or lasso penalized regression methods) will be
considered in the training set such that up to three
candidate models may be assessed in the second half of
the sample [42]. The training and testing set will be
randomly selected from the entire sample. One of these
models will be designated as primary for the formal
assessment of objective 2 before the outcomes in the test
set are unblinded. If the number of events using the split
sample approach is insufficient to develop a strong
model in the first half sample, cross-validation on the
full sample will be considered as an alternative. For in-
stance, as a rule of thumb, there should be no more than
1 predictor variable for every 10 events. Thus, before the
data are analyzed, the list of variables to be considered
may need to be trimmed.
If the selected predictors are available in the Parkinson
Progression Markers Initiative (PPMI) dataset [5], this
dataset will be used for external model validation. If this
is not possible, at least internal validation will be per-
formed using the test set and, if the model is refit on the
full data, bootstrapping.
Additional examples of a priori hypotheses that we
aim to address are, e.g.,:
 Activity levels extracted from the Verily Study
Watch in the weeks preceding a clinic visit can
predict Total and Part III scores on the MDS-
UPDRS.
 Persons with higher levels of disease burden
(including motor, affective, and cognitive symptoms)
will show decreased heart rate variability when
compared to persons with lower levels of disease
burden.
 Neurocognitive testing scores predict the
development of mild cognitive impairment [43, 44].
 Clinical motor progression in PD is the net outcome
of the shifting balance between parietal hyperactivity
(compensation) and basal ganglia hypoactivity
(primary pathophysiology).
Sample size considerations
For the first objective, we will test the association
between potential biomarkers and the deterioration of
PD on each of the two outcome domains. In this test,
both the dependent and independent variables are
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continuous measures. In order to adjust for multiple
testing issues (up to 55 biomarkers and two outcome
measures) we will use a two-sided significance level of
0.05/(2 × 55), i.e., 0.00045 instead of 0.05. In order to
detect an association with a correlation coefficient of at
least 0.2 with a power of 90%, 565 patients are needed.
Taking into account an attrition rate of 10% and missing
data for approximately 3% of patients, we aim to include
650 patients in total. If additional novel biomarkers are
selected for model consideration prior to the initiation
of analysis, power of 80% will be retained with 100 or
fewer biomarkers considered.
For the second objective we will use the dichotomous
outcomes to estimate the required sample size. We will use
a split sample approach to develop the model in the first
half of the dataset and test it on the second half of the data.
Therefore, if there are a total of 565 patients evaluable, as
dictated by the power calculation for the first objective,
there will be 282 patients available to assess the accuracy
of the model in the test set. It is desirable to demonstrate
that the accuracy is greater than 70%, i.e., the probability
that the model correctly predicts whether the patient did
or did not have an event using a pre-specified threshold, is
larger than 70%. We will have 80% power to demonstrate
that the model is more accurate than 70% if the true accur-
acy is 77% or higher. If sensitivity or specificity at a single
cut point is lower than desired for clinical utility, power
may be improved by assessing the AUC (area under the
ROC curve) rather than the accuracy at a single threshold.
Discussion
The key purpose of the Personalized Parkinson Project is
to contribute to the understanding of the differences in eti-
ology, pathophysiology, phenotypic diversity, and disease
progression among individual PD patients. Although previ-
ous cohort studies have largely contributed to elucidate the
differences between PD patients and healthy control sub-
jects [8, 45–47], we remain unable to understand the basis
for the large diversity of phenotypes and variability in pro-
gression rates among PD patients. It remains unclear why
some PD patients stay functional and independent long
into the disease, while others progress to significant motor
and/or cognitive impairment and are unable to live un-
assisted relatively early in the course of the disease. The 2-
year follow-up captures inter-individual differences in the
speed of disease progression on numerous clinically rele-
vant outcomes, including motor- and non-motor symp-
toms and endpoints that are relevant in the earlier phases
of the disease, such as the ability to work.
The PPP has several unique elements: an unbiased
approach to patient selection, with purposely broad in-
clusion criteria (also allowing for presence of co-morbid
conditions); repeated clinical, molecular, and imaging
data collection performed at a single center; and multi-
dimensional analysis to uncover novel biomarkers of PD.
A broad biomarker definition will be applied, in line
with the recently proposed modular set of biomarker as-
sessments [48]. In addition, participants will be followed
for 2 years using a wearable multi-sensor device, which
creates the opportunity to continuously monitor aggre-
gated features (e.g., daily and weekly activity level, mean
daily pulse rate and its variability, average sleep
efficiency per day) to characterize each participant over
time. The very liberal inclusion criteria, where participants
with co-morbidities are encouraged to join, allow us to
collect data from “real-life” patients and explore how co-
morbidities impair the overall expression of PD. Moreover,
although we aim for a unique dataset, to the extent pos-
sible we have harmonized data collection with previously
performed cohort studies including the Parkinson
Progression Marker Initiative [5], Luxembourg Parkinson’s
Study [11] and the Oxford Parkinson Discovery Cohort
[12]. In this manner we also support initiatives such as the
Critical Path for Parkinson’s Consortium (CPP), that aim
to create integrated unified databases, thus allowing to
increase sample sizes or add control populations and fur-
ther enhance research.
Furthermore, the PPP cohort will contribute data man-
aged through an unprecedented digital security system,
which will allow sharing of data with researchers world-
wide with maintenance of participants’ privacy. The digital
security system is based on a multi-point, privacy-by-
design strategy: (a) participants provide informed consent,
also for the important element of data sharing; (b) signed
contractual agreements with researchers are in place to
ensure that no attempts towards de-identification or
commercialization of the raw data will be attempted; (c)
governance policies restrain access to the data to only
qualified researchers; (d) an innovative pseudonymization
and encryption process is applied [35]; and (e) a protected
research environment is used to analyze the data.
Lastly, powered by Verily’s analytics capabilities, the
PPP will allow us to address research questions of great
scientific and clinical value to improve our understanding
of PD pathology and variation between patients in terms
of disease progression, therapy response (both efficacy and
tolerance), and survival. Though we will not be able to
adjust for normal age-related changes due to the lack of a
matched control group, the PPP data will help to identify
new biomarkers to predict differences in prognosis and
treatment response between patients, an important step
to improving existing treatments, developing new thera-
peutic approaches, and providing PD patients with a more
precise and personalized disease management approach.
Finally, this cohort will serve as a source of data for quali-
fied researchers worldwide, allowing them to use their
research capacity to further address and enhance the main
aims of this study.
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